LEX System^SM

Therapeutic proteins have traditionally been produced primarily in systems that use microbial cells (bacteria or yeast), or microbial systems, or that use cells from mammals, or mammalian systems. These traditional production systems, however, have a number of inherent drawbacks, including the need for significant capital investments, long lead times to establish manufacturing facilities, and high costs of production. In some instances, the commercialization of proteins has been prevented because production at commercially viable levels is not achievable in traditional systems or the use of traditional systems to produce certain proteins is blocked by existing process patents.

Demand for improved production techniques results from recent research suggesting that the efficacy and potency of monoclonal antibodies can be enhanced by modifying their glycosylation structures.

We have applied advanced genetic engineering to create our recombinant protein production system, the Lemna Expression System, or LEX System, that addresses many of the drawbacks of traditional production systems. The LEX System facilitates the development of proteins whose complexity and other properties limit their commercial viability in traditional production systems.

The LEX System also enables us to produce monoclonal antibodies that can be optimized with the objective of improving potency and efficacy.

Return to top